IJMS | Free Full-Text | Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Tepotinib granted FDA priority review for METex14 NSCLC | BLU Ampersand, Inc.
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | British Journal of Cancer
MET TKIs in METex14+ NSCLC: Tepotinib - Downloadable Slidesets - MET Inhibition in NSCLC - Oncology - Clinical Care Options
In silico docking of: (a) tepotinib (8) and TC-E 5001 (2) in MET; (b)... | Download Scientific Diagram
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases - Lung Cancer
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
c-Met inhibitor - Wikipedia
Therapeutics: tepotinib for lung cancer
Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer
Tepotinib Approved for MET+ NSCLC | Lung Cancer Foundation of America
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation - Takamori - 2021 - Thoracic Cancer - Wiley Online Library
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
Tepotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) – PRESENTATIONS | Merck
Oncology Data Advisor - Tepotinib Approved for MET-Altered Non-Small Cell Lung Cancer
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect
Ivy Elkins on Twitter: "#Tepotinib in patient derived xenografts from #NSCLC brain metastases resulted in tumor regression, including complete responses. Potentially promising for patients with brain metastases with #METamp drivers. #AACR20 #lcsm @
New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib | Merck
Tepmetko Treatment for Non Small Cell Lung Cancer - CancerConnect
Tepmetko Gets Accelerated Approval for Metastatic NSCLC - MPR
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance | Future Oncology
